Ashley Drabik
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ashley Drabik has a total of 74 co-authors. Here are the top co-authors by number of shared publications:
- Annette M. Jackson
Department of Surgery, Duke University, Durham, North Carolina, USA
4 shared publications - Cliburn Chan
Department of Biostatistics and Bioinformatics, Duke University School of Medicine, Durham, NC 27710, USA
2 shared publications - Emma Fatzaun King
Duke Transplant Center, Duke University School of Medicine, Durham, NC 27710, USA
2 shared publications - Jean Kwun
Duke Transplant Center, Duke University School of Medicine, Durham, NC 27710, USA
2 shared publications - Shengli Song
Duke University
2 shared publications - Stuart J. Knechtle
Duke Transplant Center, Department of Surgery, Duke University Medical Center, Durham, NC 27710
2 shared publications
Latest Publications
- Open Access
Profiling Allogeneic HLA-specific B-cell Responses Utilizing a 64-plex Single-HLA Reporter Cell Panel
Identifying allogeneic HLA-specific B cells in sensitized individuals is essential for defining the cellular basis of allogeneic humoral immunity but remains technically challenging due to their low frequency. To overcome this barrier, we generated a 64-plex single-HLA reporter cell (HLA64-RC) panel that provides a cost-efficient, multiplex, high-throughput platform for screening B-cell specificity. We additionally developed a companion R package, HLA64 , for automated data analysis and visualization. Integrated with a streamlined high-throughput BCR discovery workflow, this platform enables reliable identification and characterization of allogeneic HLA-specific B cells from sensitized transplant candidates. In a pilot application, thirteen HLA-specific B cells were identified, enabling linked analyses of phenotype, function, and BCR genetics. These B cells exhibited an IgG + CD24 low phenotype, diverse HLA allele-specificity profiles, and recurrent heavy- and light-chain V-gene usage. In two independent B-cell lineages, clonal members within each lineage displayed divergent binding patterns despite sharing a common clonal origin. Broader application of this approach for systematic profiling of alloreactive B-cell responses will help elucidate the molecular basis of allorecognition, define immunodominant HLA eplets, and ultimately improve immunological risk assessment and allograft outcomes in transplant recipients.
Open AccessProfiling Allogeneic HLA-specific B-cell Responses Utilizing a 64-plex Single-HLA Reporter Cell Panel
Identifying allogeneic HLA-specific B cells in sensitized individuals is essential for defining the cellular basis of allogeneic humoral immunity but remains technically challenging due to their low frequency. To overcome this barrier, we generated a 64-plex single-HLA reporter cell (HLA64-RC) panel that provides a cost-efficient, multiplex, high-throughput platform for screening B-cell specificity. We additionally developed a companion R package, HLA64 , for automated data analysis and visualization. Integrated with a streamlined high-throughput BCR discovery workflow, this platform enables reliable identification and characterization of allogeneic HLA-specific B cells from sensitized transplant candidates. In a pilot application, thirteen HLA-specific B cells were identified, enabling linked analyses of phenotype, function, and BCR genetics. These B cells exhibited an IgG + CD24 low phenotype, diverse HLA allele-specificity profiles, and recurrent heavy- and light-chain V-gene usage. In two independent B-cell lineages, clonal members within each lineage displayed divergent binding patterns despite sharing a common clonal origin. Broader application of this approach for systematic profiling of alloreactive B-cell responses will help elucidate the molecular basis of allorecognition, define immunodominant HLA eplets, and ultimately improve immunological risk assessment and allograft outcomes in transplant recipients.
- 23 October 2025
- Published by Elsevier in American Journal of Transplantation
- Vol. 26 (6) , 1363-1375
A novel immunoglobulin G- and immunoglobulin cleaving enzyme MG (IceMG), for antibody-mediated rejection
- 23 October 2025
- Published by Elsevier in American Journal of Transplantation
- Vol. 26 (6) , 1363-1375
A novel immunoglobulin G- and immunoglobulin cleaving enzyme MG (IceMG), for antibody-mediated rejection
- Open Access
Polygenic Risk Scores and HLA Class II Variants are Biomarkers of Corticosteroid Response in Childhood Nephrotic Syndrome
Introduction: Nephrotic syndrome (NS), a common glomerular disease in children, is classified based on response to corticosteroid therapy as either steroid-sensitive nephrotic syndrome (SSNS), or steroid-resistant nephrotic syndrome (SRNS). However, there are currently no reliable predictors of therapy response at initial clinical presentation. Methods: We conducted genome-wide association studies, developed polygenic risk scores (PRS) for therapy response and analyzed classical HLA alleles in 1,997 (994 discovery and 1,003 replication/validation cohorts) previously unstudied children with NS and 3,558 ancestry-matched controls. Results: A significant association with HLA loci defined by variants in HLA-DQB1, HLA-DRB1 , and HLA-DQA1 were found for SSNS (but not SRNS), along with a second immune-related SSNS locus: CLEC16A . A PRS that discriminates between SSNS and SRNS was validated in two independent cohorts. The HLA haplotype HLA-DRB1*07:01∼DQA1*02:01∼DQB1*02:02 was associated with ∼4 times the risk of developing SSNS. A model incorporating HLA haplotype, PRS score, and age at onset of the disease was the best predictor of steroid responsiveness with an AUC of 0.68-0.70 and an overall classification accuracy of SSNS versus SRNS of 67-71%. Conclusions: Our findings confirm that SSNS (unlike SRNS) is an immune-mediated HLA-associated disorder. The PRS for therapy response and HLA haplotype can serve as biomarkers and provide a foundation for more accurate diagnoses and tailored and individualized treatment. Translational statement: To identify biomarkers of pattern of steroid responsiveness in childhood-onset nephrotic syndrome, we carried out a case-control study that included over 4,000 samples, including 994 patients with NS in the discovery phase and an additional 1,003 cases from two independent replication cohorts. We identified significant risk of steroid-sensitive NS (SSNS) at HLA class II genes and CLEC16A (a gene important in the regulation of T and B lymphocytes). The HLA haplotype DRB1*07:01∼DQA1*02:01∼DQB1*02:02 was associated with four-fold increased odds of SSNS. A model incorporating HLA haplotype, polygenic risk score, and age at onset of the disease was the best predictor of steroid responsiveness providing useful delineation of steroid sensitivity from steroid resistance. In conclusion, age at onset of disease, HLA class II variants and polygenic risk scores are useful biomarkers of corticosteroid response in childhood NS and may serve as useful clinical decision support tools to guide treatment. Abstract Figure: Graphical Abstract
Open AccessPolygenic Risk Scores and HLA Class II Variants are Biomarkers of Corticosteroid Response in Childhood Nephrotic Syndrome
Introduction: Nephrotic syndrome (NS), a common glomerular disease in children, is classified based on response to corticosteroid therapy as either steroid-sensitive nephrotic syndrome (SSNS), or steroid-resistant nephrotic syndrome (SRNS). However, there are currently no reliable predictors of therapy response at initial clinical presentation. Methods: We conducted genome-wide association studies, developed polygenic risk scores (PRS) for therapy response and analyzed classical HLA alleles in 1,997 (994 discovery and 1,003 replication/validation cohorts) previously unstudied children with NS and 3,558 ancestry-matched controls. Results: A significant association with HLA loci defined by variants in HLA-DQB1, HLA-DRB1 , and HLA-DQA1 were found for SSNS (but not SRNS), along with a second immune-related SSNS locus: CLEC16A . A PRS that discriminates between SSNS and SRNS was validated in two independent cohorts. The HLA haplotype HLA-DRB1*07:01∼DQA1*02:01∼DQB1*02:02 was associated with ∼4 times the risk of developing SSNS. A model incorporating HLA haplotype, PRS score, and age at onset of the disease was the best predictor of steroid responsiveness with an AUC of 0.68-0.70 and an overall classification accuracy of SSNS versus SRNS of 67-71%. Conclusions: Our findings confirm that SSNS (unlike SRNS) is an immune-mediated HLA-associated disorder. The PRS for therapy response and HLA haplotype can serve as biomarkers and provide a foundation for more accurate diagnoses and tailored and individualized treatment. Translational statement: To identify biomarkers of pattern of steroid responsiveness in childhood-onset nephrotic syndrome, we carried out a case-control study that included over 4,000 samples, including 994 patients with NS in the discovery phase and an additional 1,003 cases from two independent replication cohorts. We identified significant risk of steroid-sensitive NS (SSNS) at HLA class II genes and CLEC16A (a gene important in the regulation of T and B lymphocytes). The HLA haplotype DRB1*07:01∼DQA1*02:01∼DQB1*02:02 was associated with four-fold increased odds of SSNS. A model incorporating HLA haplotype, polygenic risk score, and age at onset of the disease was the best predictor of steroid responsiveness providing useful delineation of steroid sensitivity from steroid resistance. In conclusion, age at onset of disease, HLA class II variants and polygenic risk scores are useful biomarkers of corticosteroid response in childhood NS and may serve as useful clinical decision support tools to guide treatment. Abstract Figure: Graphical Abstract
- 1 October 2024
- Published by Elsevier in Human Immunology
- Vol. 85 (6) , 111094
Interrogating post-transplant donor HLA-specific antibody characteristics and effector functions using clinical bead assays
- 1 October 2024
- Published by Elsevier in Human Immunology
- Vol. 85 (6) , 111094
Interrogating post-transplant donor HLA-specific antibody characteristics and effector functions using clinical bead assays